Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
3.950
+0.040 (1.02%)
Nov 21, 2024, 12:24 PM EST - Market open
Xenetic Biosciences Employees
Xenetic Biosciences had 4 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$630,857
Profits / Employee
-$1,019,315
Market Cap
6.09M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Cutera | 430 |
| Syra Health | 162 |
| Biora Therapeutics | 58 |
| Intelligent Bio Solutions | 50 |
| Healthcare Triangle | 31 |
| Adial Pharmaceuticals | 7 |
| NLS Pharmaceutics AG | 7 |
| Alzamend Neuro | 7 |
XBIO News
- 4 hours ago - Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis - Accesswire
- 8 days ago - Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - Accesswire
- 9 days ago - Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models - Accesswire
- 14 days ago - Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Accesswire
- 4 weeks ago - Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024 - Accesswire
- 5 weeks ago - Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform - Accesswire
- 2 months ago - Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - Accesswire
- 3 months ago - Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - Accesswire